[{"id":"405c722c-6da5-4af1-ae5c-65ee9d9b67ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT06746519","created_at":"2025-02-26T08:20:50.749Z","updated_at":"2025-02-26T08:20:50.749Z","phase":"Phase 1/2","brief_title":"BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia","source_id_and_acronym":"NCT06746519","lead_sponsor":"Chen Suning","biomarkers":" HOXA9 • MEIS1","pipe":"","alterations":" ","tags":["HOXA9 • MEIS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine"],"overall_status":"Recruiting","enrollment":" Enrollment 135","initiation":"Initiation: 12/25/2024","start_date":" 12/25/2024","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2024-12-24"},{"id":"46a5415c-22f8-4ee5-9a6c-fe01bd492c0b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06387082","created_at":"2024-04-26T14:50:27.501Z","updated_at":"2024-07-02T16:35:07.392Z","phase":"Phase 1","brief_title":"A Clinical Study of HMPL-506 in Patients With Hematological Malignancies","source_id_and_acronym":"NCT06387082","lead_sponsor":"Hutchmed","biomarkers":" HOXA9 • ITGAM","pipe":"","alterations":" ","tags":["HOXA9 • ITGAM"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 98","initiation":"Initiation: 05/09/2024","start_date":" 05/09/2024","primary_txt":" Primary completion: 10/08/2027","primary_completion_date":" 10/08/2027","study_txt":" Completion: 12/08/2027","study_completion_date":" 12/08/2027","last_update_posted":"2024-04-26"},{"id":"7b20d6d4-1189-47d1-bd64-55eb31d095f7","acronym":"HAP2HCT","url":"https://clinicaltrials.gov/study/NCT03849651","created_at":"2021-01-18T19:00:01.850Z","updated_at":"2024-07-02T16:35:22.870Z","phase":"Phase 2","brief_title":"TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies","source_id_and_acronym":"NCT03849651 - HAP2HCT","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" FLT3 • RUNX1 • KMT2A • ETV6 • WT1 • CREBBP • NUP98 • NSD1 • HOXA9 • NUP214 • CBFA2T3 • GLIS2 • KAT6A • KDM5A • DEK • AFDN • MLLT10","pipe":" | ","alterations":" FLT3-ITD mutation • WT1 mutation • MLL fusion • NUP98-NSD1 fusion","tags":["FLT3 • RUNX1 • KMT2A • ETV6 • WT1 • CREBBP • NUP98 • NSD1 • HOXA9 • NUP214 • CBFA2T3 • GLIS2 • KAT6A • KDM5A • DEK • AFDN • MLLT10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • WT1 mutation • MLL fusion • NUP98-NSD1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Blincyto (blinatumomab) • melphalan • fludarabine IV • mesna • thiotepa • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 01/31/2019","start_date":" 01/31/2019","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-01-19"},{"id":"4df095d5-85b3-400e-86eb-3ef2e22e4f1b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03513484","created_at":"2021-01-18T17:17:32.073Z","updated_at":"2024-07-02T16:35:25.364Z","phase":"Phase 1","brief_title":"Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT03513484","lead_sponsor":"Northwestern University","biomarkers":" FLT3 • KMT2A • CD34 • HOXA9 • FGF2","pipe":" | ","alterations":" HOXA9 overexpression","tags":["FLT3 • KMT2A • CD34 • HOXA9 • FGF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HOXA9 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • nintedanib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 11/14/2018","start_date":" 11/14/2018","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2023-12-22"},{"id":"171e6e7a-7ae1-4fff-874f-6cb21a0b852f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03701295","created_at":"2021-01-18T18:08:24.523Z","updated_at":"2024-07-02T16:35:32.967Z","phase":"Phase 1/2","brief_title":"Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement","source_id_and_acronym":"NCT03701295","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IDH1 • IDH2 • KMT2A • HOXA9 • MEIS1","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["IDH1 • IDH2 • KMT2A • HOXA9 • MEIS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • pinometostat (EPZ-5676)"],"overall_status":"Completed","enrollment":" Enrollment 1","initiation":"Initiation: 03/06/2020","start_date":" 03/06/2020","primary_txt":" Primary completion: 12/08/2020","primary_completion_date":" 12/08/2020","study_txt":" Completion: 01/12/2021","study_completion_date":" 01/12/2021","last_update_posted":"2023-10-18"}]